Comparative Pharmacology
Head-to-head clinical analysis: KALLIGA versus PROMETHAZINE DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KALLIGA versus PROMETHAZINE DM.
KALLIGA vs PROMETHAZINE DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KALLIGA is a recombinant urate oxidase enzyme that catalyzes the oxidation of uric acid to allantoin, a more soluble and easily excreted metabolite, thereby reducing serum uric acid levels.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
0.5 mg orally once daily, titrated to 1 mg once daily after 2-4 weeks if tolerated.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min)
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Renal excretion: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic